POPULARITY
19 episodes with Medicus
6 episodes with Medicus
2 episodes with Medicus
4 episodes with Medicus
2 episodes with Medicus
5 episodes with Medicus
2 episodes with Medicus
26 episodes with Medicus
2 episodes with Medicus
Der Schriftsteller Thomas Medicus hat ein außergewöhnliches Buch geschrieben. Es trägt den Titel „Vaterlos“ und wird von ihm als „Tatsachenroman“ bezeichnet. Darin erzählt Medicus vom Suizid seines Vaters und den Folgen für seine Familie. Lange konnte er sich mit diesen einschneidenden Ereignis seiner Jugend nicht auseinandersetzen. Zu groß waren der Schrecken und die Scham. Nun hat er nach vielen Wegen und Umwegen eine Form gefunden, das Schweigen zu beenden und diese Geschichte zu erzählen. Das eröffnet Wege zum Verstehen dessen, was doch ganz unverständlich ist. So kam ihm der ferne, früh verlorene Vater sehr nah. Aber auch die tief verletzte Mutter konnte er nun besser verstehen. Vor kurzem hat Thomas Medicus in der Berliner St. Matthäuskirche eine beeindruckende Kanzelrede über die Barmherzigkeit gehalten. Wir sprechen darüber, wie man dieses alte, kostbare Wort verstehen und für die Gegenwart aufschlüsseln kann, was sie mit der bildenden Kunst, der Literatur und dem Glauben zu tun hat. Und wir sprechen darüber, inwiefern sein jüngstes Buch ein „geistliches Werk der Barmherzigkeit“ darstellt.
I denne episoden av Medicuspodden har vår fertilitetscoach Mari besøk av en annen Mari, tidligere pasient hos Medicus. Dette er en viktig og fin episode om psykisk helse i møte med fertilitetsbehandling. Mari vet hva det vil si å møte negative forsøk, på negative forsøk. Men hun vet også hvor viktig det er å ta vare på seg selv og egen psykiske helse i denne prosessen.Vi håper at episoden kan normalisere, gi støtte, og inspirere deg til å ta litt ekstra vare på deg selv i en fertilitetsprosess.Vi ønsker deg god lytting!
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss two significant regulatory milestones that advance the company's pipeline in women's health and rare disease oncology. The company has submitted an Investigational New Drug (IND) application to the Department of Health – Abu Dhabi for PRECISION-E2, a first-of-its-kind Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis. The randomized, placebo-controlled study is expected to enroll approximately 84 women across multiple sites in the UAE and will leverage participants from the Emirati Genome Program, one of the world's largest national genomics initiatives. The trial is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic data, and genomic analysis to better understand treatment response variability. Researchers will evaluate three Teverelix treatment regimens with the goal of identifying the optimal dose and administration method while achieving controlled estradiol suppression within the therapeutic “Barbieri Window” and minimizing side effects such as hot flashes and bone loss. In a separate development, Medicus announced the submission of a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration for SkinJect®, its investigational doxorubicin-containing microneedle array patch, for the treatment of basal cell carcinoma in patients with Gorlin Syndrome, a rare inherited disorder associated with recurrent skin cancers. The RPDD application follows the company's previously submitted Orphan Drug Designation request and its planned registrational study design, both of which remain under FDA review. Medicus said the development strategy for Gorlin Syndrome has been shaped through consultations with clinical experts and the Gorlin Syndrome Alliance patient advocacy organization. Management believes these regulatory filings represent important steps toward advancing precision medicine approaches in both endometriosis and rare skin cancer treatment, while potentially creating new therapeutic options for patients with significant unmet medical needs. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Teverelix #Endometriosis #PrecisionMedicine #Endometriosis #GorlinSyndrome #PrecisionMedicine #Biotech #ClinicalTrials #RareDisease #DrugDevelopment
Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to discuss the company's successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS), supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer. Mehmud said the submission marks an important step in advancing Teverelix® toward registrational development, with a particular focus on prostate cancer patients who have elevated cardiovascular risk and require androgen deprivation therapy (ADT). This patient population represents a significant unmet medical need, as cardiovascular complications remain a major consideration in treatment selection and long-term management. The planned Phase 2b study is designed to optimize dose selection and further evaluate the pharmacokinetic, pharmacodynamic, efficacy, and safety profile of Teverelix® ahead of later-stage development. The data generated will help guide future registrational studies and support regulatory discussions in both Europe and the United States. Medicus has already engaged extensively with the U.S. Food and Drug Administration regarding its advanced prostate cancer development strategy, including future clinical programs focused on patients with heightened cardiovascular risk. Subject to regulatory review and approval, the company expects to begin patient enrollment later this year. Results from the study are anticipated to play a key role in determining optimal dosing, refining pivotal trial design, and advancing interactions with global regulatory agencies. Management's objective is to position Teverelix® as a best-in-class hormonal therapy specifically developed for advanced prostate cancer patients where cardiovascular safety is a critical treatment consideration. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Biotech #DrugDevelopment #FDA #Urology #BPH #AUR #MensHealth #PharmaInnovation #Healthcare #MedicalResearch #Biopharma
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a significant regulatory milestone for the company's SkinJect® program, revealing that Protocol SKNJCT-005 has been submitted to the U.S. Food and Drug Administration under the company's existing Investigational New Drug (IND) application. The submission is designed to advance SkinJect® into registrational-stage development for patients suffering from Gorlin Syndrome, a rare inherited genetic disorder characterized by the lifelong development of multiple basal cell carcinomas and recurrent skin cancers. Bokhari explained that the filing represents an important step in expanding the clinical development strategy for SkinJect® into an orphan disease indication with substantial unmet medical need. The company believes Gorlin Syndrome presents a compelling opportunity because current treatment options remain limited and there are no FDA-approved lesion-directed therapies specifically developed for patients living with the condition. Gorlin Syndrome is a rare autosomal dominant genetic disorder most commonly caused by mutations affecting the Hedgehog signaling pathway. Individuals diagnosed with the disorder may develop dozens, hundreds, or in some cases more than a thousand skin cancer lesions over their lifetime, requiring ongoing medical intervention and repeated surgical procedures. According to Bokhari, the chronic nature of the disease creates a significant burden on patients, caregivers, and healthcare systems. Repeated surgeries and treatments can lead to scarring, disfigurement, and reduced quality of life, highlighting the need for alternative treatment approaches capable of addressing individual lesions in a more targeted and patient-friendly manner. The company is also pursuing Orphan Drug Designation for the indication, which could provide several important regulatory and commercial benefits if granted by the FDA. These incentives include exemption from FDA new drug application fees, which currently exceed $5 million, as well as seven years of market exclusivity in the United States following regulatory approval. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #GorlinSyndrome #RareDisease #OrphanDrug #Biotech #SkinCancer #ClinicalTrials #DrugDevelopment #HealthcareInnovation
I dagens episode av MedicusPodden får Fertilitetscoach Mari besøk av kollega Marte fra Medicus Oslo. Marte jobber med rekruttering av egg- og sæddonorer hos Medicus – en spennende og viktig jobb. Sammen snakker de om behandling med eggdonasjon og det å bli donor. De svarer blant annet på: • Hva skjer i en eggdonasjonsbehandling? • Hvem er denne type behandling for? • Hvilke følelser og tanker er vanlige i en slik situasjon? • Hvem er kvinnene som velger å donere egg – og hva motiverer dem? Vi ønsker deg riktig god lytting!Har du ønsker om tema til podkasten? Vi ønsker gjerne forslag til tema fra deg som lytter.
This interview is disseminated on behalf of Medicus Pharma Ltd.In this episode of Stocks to Watch, we are joined by Medicus Pharma (NASDAQ: MDCX) Executive Chairman and CEO Dr. Raza Bokhari to discuss the company's promising Phase 2 results for SkinJect, its innovative skin cancer treatment, and what lies ahead for the company across oncology, rare diseases, and prostate cancer.Learn more about Medicus Pharma: https://medicuspharma.com/Watch the full YouTube interview here: https://youtu.be/4GZIBnS2KZ0And follow us to stay updated: https://www.youtube.com/GlobalOneMedia
Medicus Mundi Aragón celebra medio siglo de cooperación sanitaria internacional. Repasamos su trabajo en África y América Latina, los proyectos impulsados desde Aragón y cómo la organización combate las desigualdades sociales, sanitarias y climáticas para garantizar el acceso universal a la salud.
Jeg dro til fertilitetsklinikken Medicus for å sjekke status på fertiliteten min I januar fylte jeg 37 år, og i fjor kjøpte jeg min første leilighet i Oslo. Jeg reiser så ofte jeg kan på spennende ferier alene, har mange gode venner og en podkast jeg elsker å lage. Jeg er frisk som en fisk, kjenner av og til på ensomheten, men stort sett har jeg det kjempefint som singel
Gumo ihr Lieben zu einer BoWa-Folge, in der sich Dax und Moritz fragen, wie ihr Trip zum Deutschen Podcastaward ausgegangen sein wird – und es dann mittels Zeitreise prüfen. Noch wichtiger aber an diesem Donnerstag: Der umstrittene Kaffeeroboter Toto aus Leipzig und ein Schatzfund in einem Berliner Sandkasten. Und jetzt einschalten und genießen! Auf unserer Website findet ihr Tourtermine und Merch: https://www.bohnigerwachmacher.de/ Bitte unterstützt uns bei Steady: https://steady.page/de/bohniger-wachmacher/about/ Erhaltet einen exklusiven 15% Rabatt auf euer Saily eSIM Datenpaket! Ladet jetzt die Saily App herunter und nutzt den Code wachmacher beim Checkout vor eurer nächsten Reise, unter dem Link: https://saily.com/wachmacher Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Informationen & Rabatte Learn more about your ad choices. Visit megaphone.fm/adchoices
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss new data from a pre-specified expanded dataset analysis of the company's Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma, the most common form of skin cancer. Bokhari explained that the additional analysis builds on previously reported positive topline results, offering deeper biological, histologic, and safety insights that further strengthen the therapeutic profile of the company's SkinJect platform. He noted that the findings are consistent with earlier clinical data, including results from the Phase 1 SKNJCT-001 study conducted in 2021 and interim Phase 2 data reported in March 2025, reinforcing the reproducibility and reliability of the treatment approach across multiple studies. The SKNJCT-003 trial was designed as a randomized, double-blind, three-arm Phase 2 study evaluating two different dose levels of microneedle-delivered doxorubicin compared to a device-only control. Conducted across multiple clinical sites, the study enrolled approximately 90 patients diagnosed with nodular basal cell carcinoma, aiming to assess both safety and efficacy in a controlled setting. According to Bokhari, the expanded dataset—verified through centralized pathology review—provides a clearer and more clinically meaningful picture of treatment outcomes. Among the cohorts, the 200-microgram dose at Day 57 emerged as the most promising, demonstrating the strongest and most consistent efficacy signal. These results suggest that the treatment may offer a non-surgical alternative for certain patients, potentially reducing or delaying the need for immediate excision of cancerous lesions. Such an approach could represent a meaningful shift in the standard treatment paradigm for BCC, particularly given the relatively short treatment and evaluation window used in the study. Bokhari added that the data package could support future registration-focused discussions with the U.S. Food and Drug Administration (FDA), including considerations around optimal dosing, patient selection, lesion subtype, and treatment timelines. The company believes these findings position SkinJect as a potentially innovative and practical therapeutic option in the dermatologic oncology space. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #Oncology #MedicalInnovation #Healthcare #FDA #Biopharma
In Folge 64 des „WeissBunt Podcast – Auf der Suche nach dem Code des Lebens“ spricht Prof. Dr. Jalid Sehouli, Arzt, Wissenschaftler und Autor, mit Nico Hofmann über die Kraft des Films – und darüber, wie Geschichten Medizin fühlbar machen können. Nico Hofmann ist einer der prägendsten Film- und Fernsehproduzenten Deutschlands. Als langjähriger Geschäftsführer der UFA hat er Erfolgsproduktionen wie Der Medicus, Charité oder Unsere Mütter, unsere Väter realisiert. Seine Arbeit verbindet historische Genauigkeit mit emotionaler Erzählkraft und erreicht damit Millionen Menschen. Im Gespräch geht es um die besondere Faszination medizinischer Geschichten: Warum berühren uns Filme über Krankheit, Heilung und Menschlichkeit oft stärker als die Realität? Und wie gelingt es, komplexe medizinische Inhalte so zu erzählen, dass sie sowohl Fachleute als auch ein breites Publikum erreichen? Nico Hofmann gibt Einblicke in seine Arbeit an Produktionen wie „Der Medicus“ und „Charité“ und erklärt, wie eng Film und Medizin dabei zusammenarbeiten – von historischer Recherche bis zur Beratung durch Ärztinnen und Ärzte am Set. Dabei wird deutlich: Gute Geschichten entstehen dort, wo Wissen auf Emotion trifft. Ein zentrales Thema der Folge ist die Rolle von Empathie in der Medizin. Während moderne Gesundheitssysteme oft von Effizienz und Technik geprägt sind, zeigt der Film eine andere Perspektive: die persönliche Beziehung zwischen Arzt und Patient – und die emotionale Dimension von Krankheit und Heilung. Gemeinsam diskutieren Prof. Dr. Sehouli und Nico Hofmann auch, wie Film als Medium genutzt werden kann, um medizinisches Wissen zu vermitteln, gesellschaftliche Themen sichtbar zu machen und neue Perspektiven auf Gesundheit zu eröffnen – von historischer Aufarbeitung bis hin zu aktuellen Herausforderungen im Gesundheitswesen. Ein Gespräch über Film, Medizin und die Kraft von Geschichten – und darüber, warum echte Emotion oft der Schlüssel zum Verständnis ist. Über den Podcast Im Podcast „WeissBunt – Auf der Suche nach dem Code des Lebens“ trifft Prof. Dr. Jalid Sehouli Menschen aus Wissenschaft, Wirtschaft, Kultur und Politik zu spontanen Gesprächen ohne Skript – über Erfahrungen, Perspektiven und die Fragen, die unser Leben prägen. #WeissBunt #WeissBuntPodcast #Podcast #PodcastInterview #NicoHofmann #Medicus #Charité #Film #Storytelling #Medizin #Gesundheit #Empathie #Emotionen #Gesundheitssystem #Wissenschaft #Kultur #Inspiration #Lebenswege
Helms, Franz Paul www.deutschlandfunkkultur.de, Lesart
Helms, Franz Paul www.deutschlandfunkkultur.de, Lesart
Lesart - das Literaturmagazin (ganze Sendung) - Deutschlandfunk Kultur
Helms, Franz Paul www.deutschlandfunkkultur.de, Lesart
I denne episoden av Medicuspodden setter programleder og fertilitetscoach Mari søkelyset på mannlig fertilitet – et tema som angår langt flere enn mange tror.Hun får besøk av embryolog og lableder Steven, og fertilitetsekspert og gynekolog Alexander, som til daglig jobber med utredning og behandling av mannlig infertilitet ved Medicus.Mannlig faktor er involvert i omtrent halvparten av alle fertilitetsbehandlinger. I denne episoden snakker vi om hva menn selv kan gjøre – og hva vi hos Medicus kan hjelpe til med. Riktig god lytting!
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect® as a treatment for basal cell carcinoma in patients with Gorlin Syndrome. Bokhari explained that the submission represents a strategic expansion of the SkinJect program into a high unmet-need orphan indication, where current treatment options are limited and often require repeated surgical procedures that can lead to cumulative morbidity and disfigurement. Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare inherited disorder typically caused by mutations in the PTCH1 gene. This leads to dysregulation of the Hedgehog signaling pathway and the development of multiple, recurring skin cancers. Patients may develop dozens to more than 1,000 basal cell carcinomas over their lifetime, often beginning in childhood, creating a significant physical and psychological burden. Currently, there are no FDA-approved therapies specifically for basal cell carcinoma in patients with Gorlin Syndrome, with treatment largely reliant on surgical excision or Mohs surgery. Medicus believes SkinJect® could address this gap through a localized, repeatable, and non-surgical approach. The therapy is a doxorubicin-based dissolvable microneedle array designed for direct intradermal delivery into basal cell carcinoma lesions, targeting tumors at the site while minimizing systemic exposure. The company sees this program as an opportunity to provide a more patient-friendly treatment option for a population with significant unmet medical need. Medicus also noted it has sufficient financial runway into next year to support continued advancement of its clinical programs and key development milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #OrphanDrug #RareDisease #GorlinSyndrome #BasalCellCarcinoma #SkinCancer #Biotech #DrugDevelopment #FDA #Oncology #MedicalInnovation #Healthcare #Microneedle #PatientCare
Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to announce that the company has submitted an optimized Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix. The therapy is being developed to help prevent recurrent acute urinary retention (AUR) in men with benign prostatic hyperplasia (BPH) under the company's existing open Investigational New Drug application. Mehmud explained that the updated study design has been refined under the leadership of Steven A. Kaplan, MD, FACS, a globally recognized expert in urology and men's health, who will serve as Principal Investigator. He noted that there are currently no approved pharmacological therapies specifically indicated to prevent the recurrence of AUR, which is most caused by an enlarged prostate. Medicus Pharma's proof-of-concept approach for Teverelix aims to address this unmet need, targeting a market estimated at approximately $2 billion. The revised Phase 2 study design, known as ANT-2111-02, includes a targeted sample size of approximately 126 patients across sites in the United States and Europe. The study is designed to detect a clear pharmacodynamic signal, specifically total prostate volume reduction, within an expected timeframe of about 12 weeks. The optimized design reflects a data-driven approach, reducing the study size by roughly threefold compared to the original plan. This adjustment is expected to significantly lower development costs while improving efficiency and execution speed. The streamlined approach also positions the company for earlier strategic engagement and potential partnering discussions. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Biotech #DrugDevelopment #FDA #Urology #BPH #AUR #MensHealth #PharmaInnovation #Healthcare #MedicalResearch #Biopharma
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company's Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao's independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma's continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a rigorous framework to isolate the incremental benefit of the drug component while also assessing both visual (clinical) and histological clearance endpoints. Dr. Rao emphasized that the trial design enables a clear understanding of treatment effectiveness, combining real-world clinical observations with detailed pathological analysis. He noted that the findings carry important implications for patient care, particularly in reducing reliance on invasive procedures. One of the most compelling outcomes highlighted was that approximately three out of four treated lesions achieved visual tumor clearance. This suggests that a significant number of patients could potentially avoid immediate surgical intervention, offering a less invasive treatment alternative for certain forms of skin cancer. Dr. Rao, a dermatologist, dermatopathologist, Mohs surgeon, and clinical investigator, brings extensive expertise in skin oncology. He serves as Professor of Dermatology and Pathology and Director of Clinical Research at Rutgers Robert Wood Johnson Medical School, with additional academic roles at Weill Cornell Medical College and California Health Sciences University. The independent validation strengthens Medicus Pharma's position as it continues to develop SkinJect as a novel, minimally invasive treatment option, with the potential to reshape how certain skin cancers are managed in clinical practice #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Dermatology #SkinCancer #BasalCellCarcinoma #OncologyInnovation #Biotech #DrugDelivery #Microneedle #Doxorubicin #ClinicalResearch #HealthcareInnovation #MedicalBreakthrough #ProactiveInvestors
Navarra es la comunidad que más recursos destina por habitante a la cooperación al desarrollo y la acción humanitaria, según revela el informe elaborado por Médicos Mundi y Médicos del Mundo
Send us Fan MailIn this episode of WTR Small-Cap Spotlight, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), joins Tim Gerdeman and Robert Sassoon to walk through the company's strategy and market focus. Dr. Bokhari explains how Medicus Pharma acquires mid‑stage drug assets with existing data, reducing development risk and positioning the company for potential partnerships with larger pharmaceutical players.The conversation highlights Medicus Pharma's two lead programs aimed at major, established markets—including treatments for skin cancer and prostate‑related conditions, both representing large patient populations and significant commercial demand. Dr. Bokhari also discusses how the company is using generative AI to speed decision‑making, along with upcoming milestones and opportunities to secure non‑dilutive funding through out‑licensing.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to provide additional details from the company's Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of Basal Cell Carcinoma. The data showed the strongest treatment response in the 200-microgram cohort, which achieved 73% clinical clearance and 40% histological clearance at Day 57. The results highlight the therapeutic potential of the company's SkinJect platform, which uses microneedle technology to deliver chemotherapy directly into skin lesions without surgery. According to Medicus Pharma, the findings are particularly notable given the device-based mechanism of SkinJect. The microneedle delivery process itself may produce biological activity, which can contribute to responses even in the placebo arm of the trial. In this study, the placebo microneedle array (P-MNA) was not tip-loaded with the chemotherapeutic agent but could still stimulate a biological response due to the mechanical action of the device. The company noted that active placebo arms are not uncommon in device-drug combination trials and can be considered an acceptable regulatory data point. Importantly, the results demonstrated a clear separation in treatment response between the D-MNA therapy arm and the placebo microneedle arm in the 200-µg cohort, with clinical clearance rates of 73% and 38% respectively. Management believes the dataset represents decision-grade evidence supporting the continued advancement of the SkinJect program as a potential non-surgical treatment option for patients with basal cell carcinoma. The company plans to move forward with an End-of-Phase-2 meeting with the U.S. Food and Drug Administration to determine the optimal registrational development pathway and explore. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma #SkinJect #Biotech
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the company has released topline results from its Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of basal cell carcinoma of the skin. The company believes the topline data are not only positive but “decision-grade,” meaning they could support an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 and help accelerate potential partnering discussions. Bokhari explained that the SKNJCT-003 clinical trial was designed as a randomized, double-blind, placebo-controlled, multi-center study involving 90 patients diagnosed with nodular basal cell carcinoma. The trial compared two dose levels of the D-MNA treatment with a placebo microneedle array control to assess both safety and therapeutic effectiveness. According to the results, clearance rates improved between Day 29 and Day 57, suggesting continued biological activity of the treatment over time. The higher-dose 200 microgram cohort demonstrated the strongest response by Day 57, achieving a 73% clinical clearance rate and a 40% histological clearance rate. The reported findings reflect analysis of the study's primary and key secondary efficacy endpoints. Medicus Pharma noted that the final Clinical Study Report, which will include full safety analyses and additional procedural observations such as post-excisional biopsy site assessments, is still being compiled and is expected to be completed in the second quarter of 2026. While the final report remains in progress, the company said it does not anticipate any material changes to the efficacy findings reported in the topline results. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma
LA BIBLIOTECA DE LA HISTORIA nos abre uno de sus archivos, que nos va a acercar a: "El nombre secreto de Roma (La Sociedad Romana IX)" Hoy tenemos un nuevo programa con el escritor y divulgador histórico Ángel Portillo Lucas en el que nos va hablar de un tema muy curioso, y es el del nombre que los romanos daban a Roma, de dónde viene el nombre de Roma y muchas otras curiosidades. Sin más preámbulos os dejo con el programa y espero que os guste. Enlace al libro "Medicus": https://amzn.to/3Jzpa8A Enlace al libro "Rómulo y las Sabinas": https://amzn.to/3WDpLZR Enlace al libro "Hércules. El Dios de Trajano": https://amzn.to/3Jv7s69 Enlace al libro "Lignvm": https://amzn.to/3WDRJ7R Enlace al libro "Lignvm en Roma": https://amzn.to/3JPbPJj Enlace al libro "Lignvm en Tapae": https://amzn.to/49nPcpZ Enlace al libro "Cunina. Diosa tutelar de la infancia": https://amzn.to/4orhrsc Enlace al libro "Aliso. Los últimos supervivientes de Teutoburgo": https://amzn.to/4qMeC6O Enlace al libro "Juno y las matronas romanas": https://amzn.to/3LoJ8Dw Ángel Portillo Lucas es profesor y escritor. Tiene un blog dedicado a la divulgación de la historia de Roma, concretamente a esos aspectos menos conocidos por el público en general. Hasta el momento ha publicado ocho novelas históricas sobre la Antigua Roma, tres de ellas que pertenecen a la trilogía "LIGNVM", como son "LIGNVM" , "LIGNVM EN TAPAE" y "LIGNVM EN ROMA", otras tres novelas que pertenecen a la serie "Crónicas Romanas" como son "Cunina, Diosa tutelar de la infancia", "Aliso, los últimos supervivientes de Teutoburgo" y "Juno y las matronas romanas"; y también tiene otras dos novelas como son "Hércules, el Dios de Trajano" y "Rómulo y las Sabinas". También tiene un podcast dedicado a la divulgación histórica y es miembro de la asociación "Divulgadores de la Historia". -Blog de Ángel Portillo: http://lignumenroma.blogspot.com/ -Podcast Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html -Canal de YouTube de Ángel Portillo Lucas: https://www.youtube.com/channel/UCksX17gHXmmhRVchvrIopuQ -Canal de YouTube Sergio Alejo - Calamares a la romana: https://www.youtube.com/c/SergioAlejoGomezEscritor Este es un Podcast producido y dirigido por Gerión de Contestania, miembro del grupo "Divulgadores de la Historia". -Enlace a la página web de Divulgadores de la Historia: https://divulgadoresdelahistoria.wordpress.com/ Somos un podcast perteneciente al sello iVoox Originals. -Canal de YouTube de LA BIBLIOTECA DE LA HISTORIA: https://www.youtube.com/channel/UCfHTOD0Z_yC-McS71OhfHIA Correo electrónico: labibliotecadelahistoria@gmail.com *Si te ha gustado el programa dale al "Like", ya que con esto ayudarás a darnos más visibilidad. También puedes dejar tu comentario, decirnos en que hemos fallado o errado y también puedes sugerir un tema para que sea tratado en un futuro programa de LA BIBLIOTECA DE LA HISTORIA. Gracias. Música del audio: -Entrada: Epic Victory by Akashic Records . License by Jamendo. -Voz entrada: http://www.locutordigital.es/ -Relato: Music with License by Jamendo. Redes Sociales: -Twitter: LABIBLIOTECADE3 -Facebook: Gerión De Contestania Muchísimas gracias por escuchar LA BIBLIOTECA DE LA HISTORIA y hasta la semana que viene. Podcast amigos: Niebla de Guerra: https://www.ivoox.com/podcast-niebla-guerra_sq_f1608912_1.html La Biblioteca Perdida: https://www.ivoox.com/podcast-podcast-la-biblioteca-perdida_sq_f171036_1.html Casus Belli: https://www.ivoox.com/podcast-casus-belli-podcast_sq_f1391278_1.html Victoria Podcast: https://www.ivoox.com/podcast-victoria-podcast_sq_f1781831_1.html Relatos Salvajes: https://www.ivoox.com/podcast-relatos-salvajes_sq_f1470115_1.html Motor y al Aire: https://www.ivoox.com/podcast-motor-al-aire_sq_f1117313_1.html Pasaporte Historia: https://www.ivoox.com/podcast-pasaporte-historia_sq_f1835476_1.html Cita con Rama Podcast: https://www.ivoox.com/cita-rama-podcast-ciencia-ficcion_sq_f11043138_1.html Sierra Delta: https://www.ivoox.com/podcast-sierra-delta_sq_f1507669_1.html Permiso para Clave: https://www.ivoox.com/podcast-permiso-para-clave_sq_f1909797_1.html Héroes de Guerra 2.0: https://www.ivoox.com/podcast-heroes-guerra_sq_f1256035_1.html Calamares a la Romana: https://www.ivoox.com/podcast-calamares-a-romana_sq_f12234654_1.html Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html Bestias Humanas: https://www.ivoox.com/podcast-bestias-humanas_sq_f12390050_1.html Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals
I dagens episode har vår fertilitetscoach Mari besøk av Benedicte Haukanes. Benedicte jobber som drifts- og kvalitetsleder i Medicus. Hun har tidligere jobbet med donorkoordinering i mange år, og kan mye om donasjon og regelverk. I denne episoden gir Mari og Benedicte deg kunnskap om behandling med sæddonasjon. Du får blant annet svar på:Hvem er en typisk sæddonor? Hvem er i behov for behandling med sæddonor? Hvilke reaksjoner i form av følelser og tanker er normalt? I tillegg snakker de også om Medicus sin egen sæd- og eggbank. Vi håper du liker episoden og ønsker deg riktig god lytting. Har du ønsker for andre tema vi skal ta opp i MedicusPodden? Gi oss gjerne beskjed!
Send a textDr. Raza Bokhari, MD ( https://www.razabokhari.com/ ) is the Executive Chairman and Chief Executive Officer of Medicus Pharma Ltd. ( https://medicuspharma.com/ ), a precision-guided biotechnology company focused on accelerating the clinical development of novel and potentially disruptive therapeutic assets designed to transform the standard of care.A physician turned serial entrepreneur, Dr. Bokhari has built a distinguished career identifying, aggregating, and advancing life sciences, healthcare services, and pharmaceutical R&D companies. He is also the Managing Partner of RBx Capital, LP, an investment fund dedicated to biotech and life sciences innovation.Previously, Dr. Bokhari served as Executive Chairman and CEO of FSD Pharma, where he led a strategic transformation of the company from medicinal cannabis into a clinical-stage pharmaceutical R&D organization. Under his leadership, the company achieved a NASDAQ listing in January 2020 and raised nearly $100 million in institutional capital to support growth and expansion.Dr. Bokhari earned his Doctor of Medicine degree from Rawalpindi Medical College at the University of Punjab and holds an Executive MBA from Temple University's Fox School of Business.Beyond his corporate leadership, Dr. Bokhari is Vice Chairman of the World Affairs Council of Philadelphia. He previously served on the Board of Temple University's Fox School of Business as Chairman of the Executive Advisory Committee, and as a Trustee of both The Franklin Institute and the Foreign Policy Research Institute.Through his family foundation, Dr. Bokhari is deeply committed to philanthropy and community engagement. In recognition of a $1 million gift to Temple University, the Fox School named its Innovation & Entrepreneurship Institute Suite in his honor. In 2018, he was named a Centennial Honoree by the Fox School — recognized among a select group of entrepreneurs, visionaries, and disruptors who have shaped the institution and the broader business world since 1918.#Biotech #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #MedicusPharma #Phase2Biotech #BiotechStrategy #DeRiskThenPartner #CapitalEfficient #Investing #PharmaInvesting #PrecisionBiotech #OncologyInnovation #DrugRepurposing #MedicalInnovation #HealthcareStrategy #ClinicalDevelopment #BiotechBusinessModelSupport the show
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next-generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC). Bokhari told Proactive that the Teverelix trial will be conducted as a Phase 2b open-label study enrolling approximately 40 men with advanced prostate cancer who are appropriate candidates for androgen deprivation therapy (ADT). Patients will undergo treatment for approximately 22 weeks. The study's primary endpoint is confirmation of medical castration by Day 29, with sustained testosterone suppression maintained through Day 155. The company is targeting a probability of success exceeding 90% for achieving this endpoint. Teverelix trifluoroacetate is formulated as a long-acting injectable GnRH antagonist delivered as a microcrystalline suspension. Unlike GnRH agonists—which typically cause an initial surge in testosterone levels before suppression—Teverelix works through immediate receptor antagonism. This mechanism enables rapid suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex hormones without the testosterone “flare” associated with agonist therapies. This rapid suppression profile may hold particular clinical relevance for patients with advanced prostate cancer who are at elevated cardiovascular risk. Emerging evidence suggests that persistent FSH exposure in patients treated with GnRH agonists may contribute to adverse cardiovascular outcomes. While further clinical validation is required, prior Teverelix studies have not demonstrated significant cardiovascular safety signals to date. Cardiovascular disease remains one of the leading causes of non-cancer mortality in men with prostate cancer, accounting for approximately 30% of deaths. The risk can be further amplified during androgen deprivation therapy, particularly among patients with pre-existing cardiovascular disease. Clinical and observational data indicate that such patients may face a five- to six-fold higher incidence of major adverse cardiovascular events (MACE) when treated with GnRH agonists compared to GnRH antagonists. With FDA clearance now secured, Medicus Pharma is preparing to advance the Phase 2b study as it continues to evaluate Teverelix's potential as a differentiated therapeutic option in the treatment of advanced prostate cancer. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #Teverelix #ProstateCancer #AdvancedProstateCancer #Oncology #ClinicalTrials #Phase2b #FDA #AndrogenDeprivationTherapy #GnRH #BiotechInnovation #CardiovascularRisk #CancerResearch #DrugDevelopment #HealthcareInnovation
Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Acceso anticipado para Fans - ** VIDEO EN NUESTRO CANAL DE YOUTUBE **** https://youtu.be/qvsX06fbnZU +++++ Hazte con nuestras camisetas en https://www.bhmshop.app +++++ #historiamilitar #historia #roma El Imperio Romano parecía invencible… hasta que los bárbaros cruzaron el Danubio helado. En este programa especial, conversamos con el historiador Ángel Portillo, autor de "Medicus" ** https://amzn.to/3Jvdrr5 ** sobre su obra dedicada a uno de los conflictos más duros y menos conocidos del siglo II: las guerras marcomanas, la gran amenaza germánica al Imperio durante el reinado del emperador filósofo, Marco Aurelio. ⚔️ Analizamos dos enfrentamientos clave: - La batalla del "milagro de la lluvia", con la Legión Fulminata al borde del desastre - La emboscada en el Danubio helado, donde los germanos desataron su furia ¿Quiénes eran los marcomanos y los cuados? ️ ¿Qué papel jugó Marco Aurelio como emperador estoico y comandante militar? ¿Fue este conflicto el verdadero preludio de las futuras invasiones bárbaras? Un episodio decisivo en el que Roma se sostuvo al filo del colapso, y que reveló la crudeza de la guerra más allá del limes, en tierras salvajes donde ni las legiones ni los dioses parecían tener el control. ----------------------------------------------------------------------------------------------------------------------- COMPRA EN AMAZON CON EL ENLACE DE BHM Y AYUDANOS ************** https://amzn.to/3ZXUGQl ************* ------------------------------------------------------------------------------------------------------- LOS LIBROS DE PACO https://franciscogarciacampa.com/libros/ ------------------------------------------------------------------------------------------------------ Si queréis apoyar a Bellumartis Historia Militar e invitarnos a un café o u una cerveza virtual por nuestro trabajo, podéis visitar nuestro PATREON https://www.patreon.com/bellumartis o en PAYPAL https://www.paypal.me/bellumartis o en BIZUM 656/778/825 ---------------------------------------------------------------------------------------------------------------------- Conviértete en miembro de este canal y apoya nuestro trabajo https://www.youtube.com/channel/UCTtIr7Q_mz1QkzbZc0RWUrw/join -------------------------------------------------------------------------------------------------------------------- No olvidéis suscribiros al canal, si aún no lo habéis hecho. Si queréis ayudarnos, dadle a “me gusta” y también dejadnos comentarios. De esta forma ayudaréis a que los programas sean conocidos por más gente. Y compartidnos con vuestros amigos y conocidos. SIGUENOS EN TODAS LAS REDES SOCIALES ¿Queréis contactar con nosotros? Puedes escribirnos a bellumartispublicidad@hotmail.com como por WHATSAP o en BIZUM 656778825 Nuestra página principal es https://bellumartishistoriamilitar.blogspot.com y en la página web de Francisco García Campa https://franciscogarciacampa.com Política de Privacidad https://franciscogarciacampa.com/politica-de-privacidad/Escucha este episodio completo y accede a todo el contenido exclusivo de BELLUMARTIS PODCAST. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/618669
LA BIBLIOTECA DE LA HISTORIA nos abre uno de sus archivos, que nos va a acercar a: "Los Dioses Indigetes. Las deidades primigenias de Roma (La Sociedad Romana VIII)" Hoy tenemos un nuevo programa con el escritor y divulgador histórico Ángel Portillo Lucas en el que nos va hablar de los Dioses Indigetes, las deidades primigenias de la civilización romana a los que los romanos solicitaban su favor en todos los aspectos de la vida. Sin más preámbulos os dejo con el programa y espero que os guste. Enlace al libro "Medicus": https://amzn.to/3Jzpa8A Enlace al libro "Rómulo y las Sabinas": https://amzn.to/3WDpLZR Enlace al libro "Hércules. El Dios de Trajano": https://amzn.to/3Jv7s69 Enlace al libro "Lignvm": https://amzn.to/3WDRJ7R Enlace al libro "Lignvm en Roma": https://amzn.to/3JPbPJj Enlace al libro "Lignvm en Tapae": https://amzn.to/49nPcpZ Enlace al libro "Cunina. Diosa tutelar de la infancia": https://amzn.to/4orhrsc Enlace al libro "Aliso. Los últimos supervivientes de Teutoburgo": https://amzn.to/4qMeC6O Enlace al libro "Juno y las matronas romanas": https://amzn.to/3LoJ8Dw Ángel Portillo Lucas es profesor y escritor. Tiene un blog dedicado a la divulgación de la historia de Roma, concretamente a esos aspectos menos conocidos por el público en general. Hasta el momento ha publicado ocho novelas históricas sobre la Antigua Roma, tres de ellas que pertenecen a la trilogía "LIGNVM", como son "LIGNVM" , "LIGNVM EN TAPAE" y "LIGNVM EN ROMA", otras tres novelas que pertenecen a la serie "Crónicas Romanas" como son "Cunina, Diosa tutelar de la infancia", "Aliso, los últimos supervivientes de Teutoburgo" y "Juno y las matronas romanas"; y también tiene otras dos novelas como son "Hércules, el Dios de Trajano" y "Rómulo y las Sabinas". También tiene un podcast dedicado a la divulgación histórica y es miembro de la asociación "Divulgadores de la Historia". -Blog de Ángel Portillo: http://lignumenroma.blogspot.com/ -Podcast Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html -Canal de YouTube de Ángel Portillo Lucas: https://www.youtube.com/channel/UCksX17gHXmmhRVchvrIopuQ -Canal de YouTube Sergio Alejo - Calamares a la romana: https://www.youtube.com/c/SergioAlejoGomezEscritor Este es un Podcast producido y dirigido por Gerión de Contestania, miembro del grupo "Divulgadores de la Historia". -Enlace a la página web de Divulgadores de la Historia: https://divulgadoresdelahistoria.wordpress.com/ Somos un podcast perteneciente al sello iVoox Originals. -Canal de YouTube de LA BIBLIOTECA DE LA HISTORIA: https://www.youtube.com/channel/UCfHTOD0Z_yC-McS71OhfHIA Correo electrónico: labibliotecadelahistoria@gmail.com *Si te ha gustado el programa dale al "Like", ya que con esto ayudarás a darnos más visibilidad. También puedes dejar tu comentario, decirnos en que hemos fallado o errado y también puedes sugerir un tema para que sea tratado en un futuro programa de LA BIBLIOTECA DE LA HISTORIA. Gracias. Música del audio: -Entrada: Epic Victory by Akashic Records . License by Jamendo. -Voz entrada: http://www.locutordigital.es/ -Relato: Music with License by Jamendo. Redes Sociales: -Twitter: LABIBLIOTECADE3 -Facebook: Gerión De Contestania Muchísimas gracias por escuchar LA BIBLIOTECA DE LA HISTORIA y hasta la semana que viene. Podcast amigos: Niebla de Guerra: https://www.ivoox.com/podcast-niebla-guerra_sq_f1608912_1.html La Biblioteca Perdida: https://www.ivoox.com/podcast-podcast-la-biblioteca-perdida_sq_f171036_1.html Casus Belli: https://www.ivoox.com/podcast-casus-belli-podcast_sq_f1391278_1.html Victoria Podcast: https://www.ivoox.com/podcast-victoria-podcast_sq_f1781831_1.html Relatos Salvajes: https://www.ivoox.com/podcast-relatos-salvajes_sq_f1470115_1.html Motor y al Aire: https://www.ivoox.com/podcast-motor-al-aire_sq_f1117313_1.html Pasaporte Historia: https://www.ivoox.com/podcast-pasaporte-historia_sq_f1835476_1.html Cita con Rama Podcast: https://www.ivoox.com/cita-rama-podcast-ciencia-ficcion_sq_f11043138_1.html Sierra Delta: https://www.ivoox.com/podcast-sierra-delta_sq_f1507669_1.html Permiso para Clave: https://www.ivoox.com/podcast-permiso-para-clave_sq_f1909797_1.html Héroes de Guerra 2.0: https://www.ivoox.com/podcast-heroes-guerra_sq_f1256035_1.html Calamares a la Romana: https://www.ivoox.com/podcast-calamares-a-romana_sq_f12234654_1.html Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html Bestias Humanas: https://www.ivoox.com/podcast-bestias-humanas_sq_f12390050_1.html Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals
In this mini series, we interview resident physicians to gain a deeper understanding into the responsibilities and challenges of their chosen specialty, and if their expectations as a medical student matched up with the realities of the field. Our guest, Dr. Shawn Choe, is passionate about neurosurgery. In this episode, he shares his journey to deciding a career in neurosurgery, what the training is like, and advice on being prepared for residency.Shawn Choe, MD is a PGY-3 in the Department of Neurological Surgery at Loyola University Medical Center. Originally born in Korea and transplanted to Chicago, he calls Chicago his new home. After completing his undergraduate education at the University of Illinois Urbana-Champaign, he obtained his Master's degree at Loyola University in Chicago and later his MD from the Stritch School of Medicine prior to starting his residency. While at Stritch, he was one of the producers for Medicus.Episode produced by: Angeli MittalEpisode recording date: 9/2/25www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square, marking the one-year anniversary of Medicus' listing on the Nasdaq exchange. Dr. Bokhari said the milestone reflects the company's progress since going public and highlights its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio. Since its Nasdaq debut, Medicus has concentrated on advancing key therapeutic assets through Phase 2 proof-of-concept studies while actively pursuing licensing opportunities and strategic partnerships with established pharmaceutical companies that are well positioned to manage late-stage development and global commercialization. Medicus' current development pipeline is anchored by two lead programs. SkinJect is a localized, immunogenic precision therapy being developed for the treatment of basal cell carcinoma, the most common form of skin cancer. The company estimates SkinJect addresses a market opportunity of approximately $2 billion. The pipeline also includes Teverelix, a next-generation gonadotropin-releasing hormone (GnRH) antagonist designed for patients with advanced prostate cancer who are at high cardiovascular risk and susceptible to acute urinary retention relapse. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion. The company announced today that the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The company says this makes Teverelix more attractiveness for future partnering. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that detailed clinical data for Teverelix, the Company's long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting, taking place April 22–24 in Las Vegas, Nevada. The acceptance represents an important milestone in advancing the clinical profile of Teverelix and increasing its visibility within the endocrinology and women's health communities. Bokhari explained that the accepted abstract, titled “Evaluation of Teverelix,” summarizes results from two randomized, placebo-controlled Phase I clinical studies involving a total of 48 healthy premenopausal women. The studies were designed to assess the drug's pharmacokinetics and pharmacodynamics, including how Teverelix is absorbed, its ability to suppress key reproductive hormones, its effects on bone turnover markers, and its overall safety following a single subcutaneous injection. Across both studies, participants received single doses of Teverelix at 30 mg, 45 mg, or 60 mg, or placebo, and were monitored for approximately one month. The Phase I results demonstrated rapid and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), with hormone reductions observed within 24 hours of dosing. Estradiol suppression was dose-dependent and reversible, with multiple participants achieving levels within the clinically relevant Barbieri window of 30–50 pg/mL, a range associated with symptom control while reducing the risk of bone loss. The data also showed sustained pharmacodynamic activity, with hormone suppression lasting up to two to three weeks following a single injection at higher dose levels. Importantly, bone turnover markers remained stable throughout the observation period, suggesting no evidence of short-term bone loss. Teverelix was generally well tolerated, with a favorable safety profile, no drug-related serious adverse events, and only mild-to-moderate treatment-emergent adverse events reported. Bokhari also provided an update on Skinject, the company's flagship asset targeting non-melanoma skin cancers. He confirmed a 90-patient phase two study is complete, and that Medicus Pharma is approaching a database lock and data analysis phase, with results anticipated to align with strong interim data. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews
Medicus Pharma Chief Medical Officer Dr. Faisel Mehmud joined Steve Darling from Proactive to announce that the company has entered into a non-binding letter of intent with Reliant AI, a decision-intelligence company specializing in generative artificial intelligence for the life sciences. The proposed collaboration is focused on developing an AI-powered data analytics platform designed to enhance clinical trial execution through advanced, data-driven insights. Reliant AI is a privately held company founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, alongside life sciences expert Richard Schlegel. The company combines state-of-the-art machine learning techniques with deep biomedical expertise to automate data-intensive workflows across the life sciences, ranging from systematic literature reviews to commercial success prediction. Its platform is designed to enable biopharma teams to make faster, more informed, evidence-based decisions throughout the research and development lifecycle. Dr. Mehmud explained that the proposed platform would integrate Reliant AI's proprietary generative AI technology with Medicus' clinical, operational, and internal datasets. The goal is to strengthen data-driven decision-making across Medicus' clinical pipeline, with a particular focus on improving trial efficiency. Key anticipated capabilities include dynamic clinical-site selection, enhanced patient stratification, and more accurate enrollment forecasting. The initial phase of the collaboration is expected to focus on dynamic site selection supported by targeted patient-stratification analyses for an upcoming Teverelix clinical study, which is planned to begin in 2026. Subject to the execution of definitive agreements, Medicus expects the data analytics platform to be deployed initially in support of a Medicus-sponsored study during the Q2 to Q4 2026 period. There is also potential for the platform to be expanded to support a larger, late-stage clinical study planned for 2028, potentially in collaboration with a development or commercial partner. Medicus Pharma is currently advancing its SKNJCT-003 Phase 2 clinical study, which is being conducted across nine clinical sites in the United States. The study, which began randomizing patients in August 2024, is a randomized, double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating a non-invasive treatment for basal cell carcinoma of the skin. The study uses Medicus' novel, patent-protected, dissolvable doxorubicin-containing microneedle array (D-MNA) technology, highlighting the company's broader commitment to innovation in both therapeutic development and clinical execution. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews
Malick Bauer hat seine schauspielerischen Wurzeln sowohl in der Hamburger Off-Theaterszene als auch und auf der großen Bühne des Berliner Ensembles. Seine Vielseitigkeit beweist er in unterschiedlichsten Rollen wie in der Serie "WIR" und im "Tatort". Für seine Hauptrolle in der Serie "Sam - Ein Sachse", in der er den ersten schwarzen Polizisten in Ostdeutschland verkörpert, erhielt Malick Bauer den Grimme-Preis 2024. Jetzt ist er im Kinofilm "Medicus 2" zu sehen, der am 25. Dezember startet.
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce another major clinical milestone for the company, confirming that enrollment has been successfully completed in its Phase 2 clinical study evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA), also known as SKNJCT-003, for the non-invasive treatment of nodular basal cell carcinoma (BCC) of the skin. The Phase 2 study has enrolled a total of 90 patients across nine clinical sites in the United States and is currently underway. Completion of enrollment represents a key step forward in Medicus Pharma's development strategy, positioning the company to advance discussions with regulators and accelerate progress toward later-stage trials. Dr. Bokhari explained that the company expects to report topline results from the SKNJCT-003 study in the first quarter of 2026. Following the release of these data, Medicus Pharma plans to pursue an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 to discuss the next steps in the clinical and regulatory pathway. SKNJCT-003 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate two dose levels of the Doxorubicin Microneedle Array compared with a placebo microneedle array (P-MNA). Participants are randomized on a 1:1:1 basis into three treatment arms: a placebo group receiving P-MNA, a low-dose group receiving 100 micrograms of D-MNA, and a high-dose group receiving 200 micrograms of D-MNA. The high-dose 200 microgram D-MNA represents the maximum dose previously tested in the company's Phase 1 safety and tolerability study, SKNJCT-001, which was successfully completed in March 2021. The Phase 2 trial builds on that foundation, aiming to further validate both safety and therapeutic effectiveness in a larger patient population. Medicus Pharma's microneedle-based approach is designed to deliver chemotherapy directly into skin lesions while avoiding the need for invasive surgery, offering the potential for improved patient comfort, cosmetic outcomes, and treatment accessibility. The successful completion of enrollment marks a critical inflection point as the company advances toward potential late-stage development and regulatory engagement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews
LA BIBLIOTECA DE LA HISTORIA nos abre uno de sus archivos, que nos va a acercar a: "Medicus. La medicina en la Antigua Roma (La Sociedad Romana VII)" Hoy tenemos un nuevo programa con el escritor y divulgador histórico Ángel Portillo Lucas en el que nos va hablar de su nueva novela histórica titulada "Medicus", en la que nos sumerge en otra fascinante aventura ambientada en la Antigua Roma y en la que tenemos como base fundamental cómo era vista y usada la medicina en aquella sociedad de las que nos separan casi dos mil años de historia. Sin más preámbulos os dejo con el programa y espero que os guste. Enlace al libro "Medicus": https://amzn.to/3Jzpa8A Enlace al libro "Rómulo y las Sabinas": https://amzn.to/3WDpLZR Enlace al libro "Hércules. El Dios de Trajano": https://amzn.to/3Jv7s69 Enlace al libro "Lignvm": https://amzn.to/3WDRJ7R Enlace al libro "Lignvm en Roma": https://amzn.to/3JPbPJj Enlace al libro "Lignvm en Tapae": https://amzn.to/49nPcpZ Enlace al libro "Cunina. Diosa tutelar de la infancia": https://amzn.to/4orhrsc Enlace al libro "Aliso. Los últimos supervivientes de Teutoburgo": https://amzn.to/4qMeC6O Enlace al libro "Juno y las matronas romanas": https://amzn.to/3LoJ8Dw Ángel Portillo Lucas es profesor y escritor. Tiene un blog dedicado a la divulgación de la historia de Roma, concretamente a esos aspectos menos conocidos por el público en general. Hasta el momento ha publicado ocho novelas históricas sobre la Antigua Roma, tres de ellas que pertenecen a la trilogía "LIGNVM", como son "LIGNVM" , "LIGNVM EN TAPAE" y "LIGNVM EN ROMA", otras tres novelas que pertenecen a la serie "Crónicas Romanas" como son "Cunina, Diosa tutelar de la infancia", "Aliso, los últimos supervivientes de Teutoburgo" y "Juno y las matronas romanas"; y también tiene otras dos novelas como son "Hércules, el Dios de Trajano" y "Rómulo y las Sabinas". También tiene un podcast dedicado a la divulgación histórica y es miembro de la asociación "Divulgadores de la Historia". -Blog de Ángel Portillo: http://lignumenroma.blogspot.com/ -Podcast Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html -Canal de YouTube de Ángel Portillo Lucas: https://www.youtube.com/channel/UCksX17gHXmmhRVchvrIopuQ -Canal de YouTube Sergio Alejo - Calamares a la romana: https://www.youtube.com/c/SergioAlejoGomezEscritor Este es un Podcast producido y dirigido por Gerión de Contestania, miembro del grupo "Divulgadores de la Historia". -Enlace a la página web de Divulgadores de la Historia: https://divulgadoresdelahistoria.wordpress.com/ Somos un podcast perteneciente al sello iVoox Originals. -Canal de YouTube de LA BIBLIOTECA DE LA HISTORIA: https://www.youtube.com/channel/UCfHTOD0Z_yC-McS71OhfHIA Correo electrónico: labibliotecadelahistoria@gmail.com *Si te ha gustado el programa dale al "Like", ya que con esto ayudarás a darnos más visibilidad. También puedes dejar tu comentario, decirnos en que hemos fallado o errado y también puedes sugerir un tema para que sea tratado en un futuro programa de LA BIBLIOTECA DE LA HISTORIA. Gracias. Música del audio: -Entrada: Epic Victory by Akashic Records . License by Jamendo. -Voz entrada: http://www.locutordigital.es/ -Relato: Music with License by Jamendo. Redes Sociales: -Twitter: LABIBLIOTECADE3 -Facebook: Gerión De Contestania Muchísimas gracias por escuchar LA BIBLIOTECA DE LA HISTORIA y hasta la semana que viene. Podcast amigos: Niebla de Guerra: https://www.ivoox.com/podcast-niebla-guerra_sq_f1608912_1.html La Biblioteca Perdida: https://www.ivoox.com/podcast-podcast-la-biblioteca-perdida_sq_f171036_1.html Casus Belli: https://www.ivoox.com/podcast-casus-belli-podcast_sq_f1391278_1.html Victoria Podcast: https://www.ivoox.com/podcast-victoria-podcast_sq_f1781831_1.html Relatos Salvajes: https://www.ivoox.com/podcast-relatos-salvajes_sq_f1470115_1.html Motor y al Aire: https://www.ivoox.com/podcast-motor-al-aire_sq_f1117313_1.html Pasaporte Historia: https://www.ivoox.com/podcast-pasaporte-historia_sq_f1835476_1.html Cita con Rama Podcast: https://www.ivoox.com/cita-rama-podcast-ciencia-ficcion_sq_f11043138_1.html Sierra Delta: https://www.ivoox.com/podcast-sierra-delta_sq_f1507669_1.html Permiso para Clave: https://www.ivoox.com/podcast-permiso-para-clave_sq_f1909797_1.html Héroes de Guerra 2.0: https://www.ivoox.com/podcast-heroes-guerra_sq_f1256035_1.html Calamares a la Romana: https://www.ivoox.com/podcast-calamares-a-romana_sq_f12234654_1.html Lignvm en Roma: https://www.ivoox.com/podcast-lignum-roma_sq_f1828941_1.html Bestias Humanas: https://www.ivoox.com/podcast-bestias-humanas_sq_f12390050_1.html Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals
⚠️ Uwaga:Nie opowiadam w nim całej historii głównego bohatera, ani nie zdradzam zakończenia. – bo tego masz doświadczyć sam, po własnej lekturze. Ale obiecuję: to, co usłyszysz, zmieni Twój sposób myślenia o determinacji.Jeśli jednak nie chcesz nic wiedzieć o jej głównym bohaterze, nie słuchaj tego odcinka.
¡Vótame en los Premios iVoox 2025! Retomamos el tema con el que arrancamos la presente temporada hace unas semanas: la unificación de Japón. Con la sabia guía de Rubén Ibarzabal, ya os explicamos la era Sengoku, caracterizada por el caos bélico con señores de la guerra luchando por doquier. Hoy conoceremos a los tres grandes nombres que lograron poner fin a ese periodo, con el anhelo de establecer un mando unificado en el país del sol naciente. Hablamos de Oda Nobunaga, Toyotomi Hideyoshi y Tokugawa Ieyasu. La segunda propuesta nos lleva a conocer el oficio de galeno en la antigua Roma. Y nunca mejor dicho, porque el hombre que llegó su nombre al vocabulario como sinónimo de médico, tiene su papel en la última novela de Ángel Portillo, Medicus, publicada el pasado verano. Lo entrevistamos para conocer todos sus entresijos. En la repetición, esta semana recuperamos la tercera parte de la saga sobre los cosacos. Tras repasar su forma de vida retomamos el repaso a la historia de este pueblo. Partiendo del siglo XVII nos detendremos en las rebeliones protagonizadas por cosacos, recordaremos su notable participación en la campaña rusa de Napoleón y veremos su rol en la conquista del Cáucaso y de Asia Central. Cerramos la entrega a las puertas de la Revolución Rusa de 1917. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals
Philipp Medicus setzt bei der Entwicklung von Gleitschirmen für Nova stark auf die Hilfe von Simulationsprogrammen. Was bringt das? +++ Es gab eine Zeit, da war die Konstruktion von Gleitschirmen vor allem ein Handwerk. Da wurden Profile noch aus Pappe geschnitten, um dann darauf die Tuchbahnen abzuwickeln und so letztendlich zu den Schnittmustern zu kommen. Und wenn es gut lief, sank so ein Schirm am Ende nicht nur mit Gleitzahl eins zu Stein vom Himmel. Im modernen Gleitschirmbau ist der Computer zum vielleicht wichtigsten Werkzeug der Konstrukteure geworden. Immer mehr spielen dabei nicht nur CAD-Software, sondern auch komplexere Simulationen der Strömungsdynamik eine Rolle. Philipp Medicus von Nova geht sogar noch einen Schritt weiter. Er nutzt Programme, die die dynamische Verformung eines Gleitschirms berechnen können, wenn aerodynamischen Kräfte ins Wechselspiel treten mit Dutzenden anderer technischer Parameter, die einen Gleitschirm ausmachen: Profilform, Zellenzahl, Leinenlayout, Querzugbänder, Diagonalrippen, 3D-Shaping, Mini-Ribs, etc. In dieser Episode 170 von Podz-Glidz erzählt Philipp Medicus, wie diese Herangehensweise ihm dabei hilft, Gleitschirme zu bauen, die auch in bewegter, turbulenter Luft noch möglichst stabil und leistungsstark bleiben. Im Gespräch geht es auch um Fragen wie: Wann ist das Konzept Gleitschirm auskonstruiert? Wie entsteht eigentlich ein Pflichtenheft für ein neues Modell? Und welche Rolle spielt heute schon KI in der Entwicklung von Gleitschirmen? +++ Werde zum Förderer von Podz-Glidz und dem Blog Lu-Glidz. Alle Infos: https://lu-glidz.blogspot.com/p/fordern.html +++ Musik dieser Folge: Track: Spatial Entaglement | Künstler: The Grey Room Youtube Audio Library https://www.youtube.com/watch?v=s5VdA6spQeY +++ Lu-Glidz Links: + Blog: https://lu-glidz.blogspot.com + Facebook: https://www.facebook.com/luglidz + Instagram: https://www.instagram.com/luglidz/ + Whatsapp-Kanal: https://whatsapp.com/channel/0029VaBVs05CHDynzdlJlU34 + Youtube: https://youtube.com/@Lu-Glidz + Soundcloud: https://soundcloud.com/lu-glidz + Spotify: https://open.spotify.com/show/6ZNvk83xxGHHtfgFjiAHyJ + Apple-Podcast: https://itunes.apple.com/de/podcast/podz-glidz-der-lu-glidz-podcast/id1447518310?mt=2 + Linktree: https://linktr.ee/luglidz +++ LINKS zu Philipp Medicus + Nova: https://www.nova.eu + Vortrag Thermikmesse zu neuen Möglichkeiten in der Gleitschirmentwicklung: https://www.youtube.com/watch?v=mUZD5Tij1SA
Michael Kirsty of the Friends of Chamber Music Troy is in conversation about upcoming Medicus Memorial Concert Hudson Mohawk Magazines' Andrea Cunliffe asked about the scheduling of artists in these turbulent times when all the Arts need sustaining.. For more information: Friends of Chamber Music.org Medicus Memorial Concert takes place on Wed, Mar 26 @ 7:00 PM at Main Stage, Performing Arts Center, University at Albany SUNY
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Download the transcript here
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Listen to the podcast here
In this episode of Medicus, we're diving into the world of integrative medicine—a healthcare approach that goes beyond symptom management to treat the whole person. We talk with Dr. Jennifer Ron, an emergency medicine and integrative medicine physician about her practice. Join us as we explore how traditional medicine can work hand-in-hand with integrative practices to offer a more holistic path to health and wellness. Whether you're curious about what integrative medicine really means, looking for insights on how nutrition impacts health, or interested in how these practices can work within a traditional medical framework, this episode has something for everyone. Tune in and discover how integrative medicine might just be the key to creating a healthcare system that truly heals. To learn more about Dr. Ron's EPEP program, you can visit her website at: https://www.healingcancerfromwithin.com Episode produced by: Griffin K Johson Episode recording date: 10/07/2024 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate
Fr. Wade Menezes talks about his new book, Stand Firm, Be Strong: A Men's Catholic Daily Devotional, scheduled for release on November 1st and Louis Brown, executive director of the Christ Medicus Foundation shares news about this Thursday's launch of a Policy Agenda for Religious Freedom in Health Care.
The autopsy has wide-ranging benefits on medicine, public health, and research. However, the rates of autopsies performed in the hospital have declined tremendously over the past several decades. The autopsy, accordingly, is often overlooked in medical education today. Emily Hagen, MD, has taken great interest in this. In this episode, we speak with Emily (former Medicus producer!) about her firsthand experiences with the autopsy, dating back to her pre-med days and continuing throughout her time at Stritch School of Medicine. She is a fierce advocate for the autopsy's incorporation into medical education. While a medical student, Emily researched non-pathologist physicians' experiences with and views toward the autopsy and she launched an autopsy observation program for Loyola medical students. The associated research has been presented at multiple academic conferences. She also helped to curate Autopsy/Forensic Pathology modules for the PathElective, an internationally utilized resource. As an aspiring internist, Emily discusses the relevance of the autopsy to physicians and the medical community at large. Tune in now to learn more about this important and interesting topic! To connect with Emily, email her at esh73@cornell.edu. Episode produced by: Rasa Valiauga Episode recording date: 6/4/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate
In this episode, host Julien Stroumza sits down with Medicus member Jackie Tarsitano to discuss the alarming rise of genetic testing fraud, a multibillion-dollar scam that targets Medicare beneficiaries. Tune in as they explore the financial and ethical implications of this deceptive practice, shedding light on its impact on patients, healthcare providers, and the system as a whole. Jackie can be reached at jtarsitano@luc.edu Episode produced by: Jackie Tarsitano Episode recording date: 6/15/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate
Czy kiedykolwiek zastanawiałeś się, jak powieść historyczna może zmienić Twoje życie?Jeśli tak, to mam dla Ciebie coś specjalnego!W najnowszym odcinku mojego podcastu zabiorę Cię w fascynującą podróż przez karty „Medicusa” Noaha Gordona i pokażę, jak ta niezwykła książka może stać się Twoim osobistym narzędziem rozwoju.Dowiesz się m. in:Jak historia młodego lekarza z XI wieku może zainspirować Was do realizacji własnych marzeńDlaczego czytanie powieści historycznych to więcej niż rozrywka – to trening dla umysłu i duchaJak „Medicus” uczy nas odwagi, determinacji i otwartości na światW jaki sposób możesz wykorzystać lekcje z książki w swoim codziennym życiuPoznasz też moje osobiste doświadczenia z tą lekturą i dowiesz się, jak wpłynęła na moje postrzeganie świata i siebie samego.To nie jest zwykła recenzja książki.To praktyczny przewodnik po tym, jak literatura piękna może stać się Twoim sprzymierzeńcem w drodze do lepszego, bardziej świadomego życia.Gwarantuję, że po jego wysłuchaniu spojrzysz na czytanie z zupełnie nowej perspektywy.Pamiętaj!Subskrybuj „Porannik Kreatywny”, aby nie przegapić kolejnych historii i praktycznych porad.Jeśli chcesz być na bieżąco z nowymi odcinkami i inspirującymi historiami, koniecznie subskrybuj mój podcast i dołącz do wspólnoty Lepiej Teraz na Patronite!Zapraszam Cię do dołączenia do grona Patronek i Patronów z Patronite.pl, gdzie znajdziesz nigdzie niepublikowane odcinki podcastu oraz specjalny Newsletter.Będę bardzo wdzięczny, jeśli do nich dołączysz!
In this 4th year medical student (MS4) series, we discuss the field of Psychiatry. Our guest, Julia Versel, shares advice on how to set yourself up for success regarding matching into this increasingly competitive specialty and shares tips to help you stand out both on paper and in person. Julia Versel, MD, MSc is a current resident at Brigham and Women's Hospital/Harvard Medical School Psychiatry Residency Program. She is passionate about medical education, with a particular interest in incorporating medical student mentorship into her career. Please reach out to the Medicus team if you would like to get in touch with her! To learn more about the field, check out these resources: Psychiatry Student Interest Group Network (PsychSIGN): https://www.psychsign.org/ AADPRT Psychiatry Training Resources: https://www.aadprt.org/trainees/psychiatry-training APA Roadmap to Applying for Psychiatry Residency: https://www.psychiatry.org/getmedia/b7007db1-b815-45fa-93bd-1f1eaf3dff99/APA-Roadmap-to-Psychiatric-Residency.pdf APA Resources for Medical Students: https://www.psychiatry.org/residents-medical-students/medical-students Episode produced by: Rasa Valiauga Episode recording date: 4/25/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate
Pastor Mattie teaches on the Christus Medicus model of the atonement, painting a picture of the Cross as not only a means to our deliverance and forgiveness, but also our healing. Support the Show.
© 2020-2026 Ivy Podcast Discovery LLC
